Pyelonephritis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Pyelonephritis Market Outlook

Thelansis’s “Pyelonephritis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pyelonephritis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pyelonephritis Overview

Infection and swelling of the kidney and renal pelvis are called pyelonephritis. Pyelonephritis is a potentially catastrophic complication of transplantation. Pyelonephritis can result in graft loss and manifest as acute renal failure. Based on a single series, 80% of bouts of pyelonephritis occur a year or more after transplantation, with E. Coli being the most prevalent pathogen in 80% of cases. When pyuria is present, flank discomfort and soreness strongly suggest pyelonephritis and help to distinguish it from other UTIs. Every patient should have a urine culture and antimicrobial susceptibility testing; if clinically appropriate, the urine culture should be completed before the patient receives antibiotics. A significant inflammatory response to renal parenchymal infection in pyelonephritis leads to swelling that modifies normal tissue characteristics and efficiency. A urinalysis and culture with sensitivity testing are necessary for all patients with suspected pyelonephritis. Outpatient therapy is appropriate for patients with a mild infection who do not have a fever or other systemic symptoms. Any patient who meets the criteria for a complex infection (such as those who are immunocompromised, have urinary tract anomalies, or have an infection related to urologic surgery) or who might not comply should be admitted, as should all other patients. deliver radiologic contrast agent to the location, causing uptake on a nuclear cortex scan.

• Acute pyelonephritis in the US is estimated to be at a rate of 15 to 17 cases per 10,000 females and 3 to 4 cases per 10,000 males per year.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: